Kidney Medicine最新文献

{"title":"Pretransplant Cognitive Function and Kidney Transplant Outcomes: A Prospective Cohort Study","authors":"Aditi Gupta , Michael J. Grasing , Kate J. Young , Robert N. Montgomery , Daniel J. Murillo , Diane M. Cibrik","doi":"10.1016/j.xkme.2024.100872","DOIUrl":"10.1016/j.xkme.2024.100872","url":null,"abstract":"<div><h3>Background & Hypothesis</h3><p>Cognitive impairment is common in patients being evaluated for a kidney transplant (KT). The association between pretransplant cognitive function and posttransplant outcomes is unclear.</p></div><div><h3>Study Design</h3><p>We performed a prospective cohort study to assess the association between pretransplant cognitive function and clinically relevant posttransplant outcomes.</p></div><div><h3>Setting and Population</h3><p>In this single center study, participants from the transplant clinic were evaluated during their pretransplant clinic visits and followed prospectively.</p></div><div><h3>Outcomes</h3><p>Our primary outcome measure was allograft function. Secondary outcomes were length of hospitalization for KT, hospital readmission within 30 and 90 days, graft loss, graft rejection within 90 days and 1 year, and mortality.</p></div><div><h3>Analytic Approach</h3><p>We measured cognitive function with the Montreal Cognitive Assessment (MoCA) test. We assessed the association of pretransplant MoCA score with posttransplant outcomes; we used linear mixed effects models to assess the association with the change in estimated glomerular filtration rate, Poisson regression for length of hospitalization, Cox proportional hazard model for graft loss and mortality, and a logistic regression model for readmission and rejection.</p></div><div><h3>Results</h3><p>We followed 501 participants for 2.7<!--> <!-->±<!--> <!-->1.5 years. The mean age of the patients was 53<!--> <!-->±<!--> <!-->14 years and the mean pretransplant MoCA score was 25<!--> <!-->±<!--> <!-->3. Lower pretransplant MoCA scores did not adversely affect the primary outcome of allograft function or the secondary outcomes. Although higher MoCA scores predicted a higher decline in graft function (β =<!--> <!-->−0.28, 95% CI: −0.55 to<!--> <!-->−0.01, <em>P</em> <!-->=<!--> <!-->0.04), the effect was small and not clinically significant. Older age was associated with longer hospitalization, lower likelihood of rejection, and higher mortality. Deceased donor KT (vs living donor KT) was associated with longer hospitalization but better graft function. Longer time receiving dialysis before KT was associated with longer hospitalization. A history of diabetes mellitus was associated with higher mortality.</p></div><div><h3>Limitations</h3><p>Single center study limiting generalizability.</p></div><div><h3>Conclusions</h3><p>Pretransplant MoCA scores were not associated with the primary outcome of allograft function or the secondary outcomes.</p></div><div><h3>Plain-Language Summary</h3><p>Cognitive impairment (problems with memory and thinking) is common in patients with kidney disease. Cognitive impairment is associated with problems following instructions and remembering to take medications. Medical adherence is important in kidney transplant recipients, and inability to follow instructions and missed doses of immunosuppression increases the risk of r","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000839/pdfft?md5=3b98778245197e9c2fd9b4c34cd4681f&pid=1-s2.0-S2590059524000839-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141841337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Kidney Transplant from Donors with Sickle Cell Disease: A Case Series of Six Transplants","authors":"Prathap Kumar Simhadri ,&nbsp;Felicitas Koller ,&nbsp;Praise Matemavi ,&nbsp;Mark Truman Earl ,&nbsp;Deepak Chandramohan ,&nbsp;Pradeep K. Vaitla","doi":"10.1016/j.xkme.2024.100875","DOIUrl":"10.1016/j.xkme.2024.100875","url":null,"abstract":"<div><p>People with sickle cell disease experience a high incidence of chronic kidney disease and end-stage kidney disease, secondary to tubular and glomerular effects of vaso-occlusion-induced hypoxia. Because of concerns of suboptimal kidney function, sickle cell donors are usually not considered for kidney donation, even if the rest of the parameters are acceptable for organ donation. A significant gap exists between the number of organ donors and the number of candidates waiting for a kidney transplant in the United States. To bridge the gap, we need to consider using nontraditional donors. We report kidney transplant outcomes in 6 recipients from 4 sickle cell kidney donors. Intracranial hemorrhage and sepsis were the causes of the death in donors, and no donor was in sickle cell crisis at the time of donation. None of the recipients experienced delayed graft function, and all recipients achieved excellent allograft function. The earliest allograft failure was at 27 months in a recipient who developed early acute rejection, while the longest follow-up was 10 years with adequate kidney function. In conclusion, given the shortage of kidneys for transplantation and demonstrated good outcomes, we propose that kidneys from sickle cell donors can be safely used.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000864/pdfft?md5=0bf383d3423f5d044974a37bff6b7765&pid=1-s2.0-S2590059524000864-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complement Receptor 1 Enhancement in Recurrent Membranous Nephropathy Following Kidney Transplantation: A Case Report","authors":"Noriyuki Kounoue ,&nbsp;Hideyo Oguchi ,&nbsp;Akinori Hashiguchi ,&nbsp;Kazuho Honda ,&nbsp;Dedong Kang ,&nbsp;Tetuo Mikami ,&nbsp;Naobumi Tochigi ,&nbsp;Takeshi Kawamura ,&nbsp;Yoshihiro Itabashi ,&nbsp;Takashi Yonekura ,&nbsp;Kei Sakurabayashi ,&nbsp;Ken Sakai","doi":"10.1016/j.xkme.2024.100876","DOIUrl":"10.1016/j.xkme.2024.100876","url":null,"abstract":"<div><p>Membranous nephropathy (MN) recurs in some kidney allograft patients, and recurrence increases graft failure rates. We present a unique case of recurrent MN in first and second allografts showing glomerular capillary wall-positivity for complement receptor 1 (CR1) consistent with immunoglobulin G (IgG). A man in his late 20s developed MN and started hemodialysis. MN recurred and caused graft loss after the first transplantation and recurred again soon after the second transplantation. The IgG subclass staining was almost consistently negative for IgG4 and phospholipase A2 receptor (PLA2R)-staining was negative. Recurrent MN of unknown etiology was considered. Mass spectrometry demonstrated that CR1 had increased in the transplanted kidney biopsies. Immunohistochemistry and immunofluorescence studies demonstrated CR1 colocalized with IgG along glomerular capillaries in this case, whereas CR1 was localized in podocytes with no colocalization of IgG in a control case of PLA2R-associated MN. Correlative light and immunoelectron microscopy showed localization of CR1 at the interface between electron-dense deposits and podocytes. Collectively, this case demonstrated a unique enhancement and localization of CR1. MN with enhancement of CR1 has not been reported to date. CR1 may be a candidate causative antigen in this case of recurrent MN, although further study is needed to investigate the pathogenesis of CR1.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000876/pdfft?md5=99c54f2c786c376f4d641d6f93f86b03&pid=1-s2.0-S2590059524000876-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Resource for Health Professionals to Raise Advance Care Planning Topics During Kidney Care Consultations: A Multiple User-Centered Design","authors":"Anna Winterbottom ,&nbsp;Helen Hurst ,&nbsp;Fliss E.M. Murtagh ,&nbsp;Hilary L. Bekker ,&nbsp;Paula Ormandy ,&nbsp;Barnaby Hole ,&nbsp;Lynne Russon ,&nbsp;Emma Murphy ,&nbsp;Keith Bucknall ,&nbsp;Andrew Mooney","doi":"10.1016/j.xkme.2024.100874","DOIUrl":"10.1016/j.xkme.2024.100874","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;p&gt;Planning and delivering treatment pathways that integrate end-of-life care, frailty assessment, and enhanced supportive care is a service priority. Despite this, people with kidney failure are less likely to have an advance care plan and receive hospice and palliative care compared with other chronic illness populations. This is linked to health professionals feeling unskilled initiating conversations around future treatment and care options. This article describes research underpinning the development of a guide for kidney health professionals discussing end-of-life and advance care planning options with people with kidney failure and family members.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;p&gt;The study comprised 2 parts: an initial cross-sectional qualitative approach using in-depth interviews with older adults with kidney failure and (bereaved) carers followed by resource development with input from multiple stakeholders.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;p&gt;Older adults with kidney failure and (bereaved) carers recruited from 2 renal units in the North of England and by online advertisements with national United Kingdom-based kidney patient charities. Resource development included input from co-applicants, independent advisory committee, patient and public involvement team, multidisciplinary health professionals and academics in the United Kingdom and Denmark.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;p&gt;Thematic analysis was used to analyze the data.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Twenty-seven people were interviewed: older adults with kidney failure (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;18), carers (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;5), bereaved carers (n&lt;!--&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;4). Five themes are described: the context within which end-of-life conversations take place, preferences for end-of-life treatment and care, family members’ role and needs in supporting people with kidney failure at the end-of-life, expectations and experience of dialysis treatment, and beliefs and experiences of death and dying.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;p&gt;Participants were mainly White, British, and receiving hemodialysis.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;p&gt;People with (lived) experience of kidney failure informed a guide which aims to build on health professionals existing skills and improve confidence having conversations about future treatment and care. Kidney teams have expressed interest implementing the guide in practice and within their broader communications training packages.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain-Language Summary&lt;/h3&gt;&lt;p&gt;Delivering treatment pathways integrating end-of-life care, frailty assessment, and enhanced supportive care is a service priority. Despite this, people with kidney failure are less likely to have an advance care plan and receive hospice and palliative care compared with other chronic illness populations. This article describes how people with (lived) experience of kidney failure informed a guide ","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000852/pdfft?md5=2a9b9e5b93da61b841531a122abccfd9&pid=1-s2.0-S2590059524000852-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Costs Across Diabetic Kidney Disease Stages: A Veterans Affairs Study","authors":"Kibum Kim ,&nbsp;Jacob Crook ,&nbsp;Chao-Chin Lu ,&nbsp;Heather Nyman ,&nbsp;Jyotirmoy Sarker ,&nbsp;Richard Nelson ,&nbsp;Joanne LaFleur","doi":"10.1016/j.xkme.2024.100873","DOIUrl":"10.1016/j.xkme.2024.100873","url":null,"abstract":"<div><h3>Background</h3><p>In the United States, diabetic kidney disease (DKD) affects about one-third of individuals with type 2 diabetes, causing significant economic burdens on the health care system and affecting patients’ quality of life.</p></div><div><h3>Objective</h3><p>The aim of the study was to quantify the burden of care in patients at different stages of DKD and to monitor shifts in healthcare costs throughout these stages.</p></div><div><h3>Methods</h3><p>This study used data from the Veterans Affairs National database, focusing on US veterans diagnosed with DKD between January 2016 and March 2022. Aggregated all-cause health care costs per month were summarized using descriptive statistics. We used a generalized linear model to calculate the cost of DKD patent care based on the stages, dialysis phase, and kidney replacement therapy.</p></div><div><h3>Results</h3><p>The cohort of 685,288 patients with DKD was predominantly male (96.51%), White (74.42%), and non-Hispanic (93.54%). The mean (SD) per-patient per-month costs were $1,597 ($3,178), $1,772 ($4,269), $2,857 ($13,072), $3,722 ($12,134), $5,505 ($14,639), and $6,999 ($16,901) for stages 1, 2, 3a, 3b, 4 and 5 respectively. The average monthly expenditure for patients receiving long-term dialysis was $12,299. Costs peaked sharply during the first month of kidney replacement therapy at $38,359 but subsequently decreased to $6,636 after 1 year.</p></div><div><h3>Conclusions</h3><p>The economic implications of DKD are profound, emphasizing the need for efficient early detection and disease management strategies. Preventing patients from progressing to advanced DKD stage will minimize the economic repercussions of DKD and will assist health care systems in optimizing resource allocation.</p></div><div><h3>Plain-Language Summary</h3><p>Diabetic kidney disease (DKD) places a substantial burden on health care systems in the United States. In part of our effort to close the knowledge gap around the disease burden, care cost analysis for the patients with DKD was performed for US veterans. Along with stage progression, overall care costs per-patient per-month drastically increases from $1,597 (stage 1) to $6,999 (stage 5). Monthly costs exceeded $10,000 once veterans started to receive long-term dialysis. The quantitative summary will help health care systems efficiently allocate resources across various disease sectors.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000840/pdfft?md5=4c53ed228f9294694e8b1f593960e3ca&pid=1-s2.0-S2590059524000840-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemodialysis Vascular Access: A Historical Perspective on Access Promotion, Barriers, and Lessons for the Future","authors":"Anatole Besarab ,&nbsp;Stanley Frinak ,&nbsp;Suresh Margassery ,&nbsp;Jay B. Wish","doi":"10.1016/j.xkme.2024.100871","DOIUrl":"10.1016/j.xkme.2024.100871","url":null,"abstract":"<div><p>This review describes the history of vascular access for hemodialysis (HD) over the past 8 decades. Reliable, repeatable vascular access for outpatient HD began in the 1960s with the Quinton-Scribner shunt. This was followed by the autologous Brecia-Cimino radial-cephalic arteriovenous fistula (AVF), which dominated HD vascular access for the next 20 years. Delayed referral and the requirement of 1.5-3 months for AVF maturation led to the development of and increasing dependence on synthetic arteriovenous grafts (AVGs) and tunneled central venous catheters, both of which have higher thrombosis and infection risks than AVFs. The use of AVGs and tunneled central venous catheters increased progressively to the point that, in 1997, the first evidence-based clinical practice guidelines for HD vascular access recommended that they only be used if a functioning AVF could not be established. Efforts to promote AVF use in the United States during the past 2 decades doubled their prevalence; however, recent practice guidelines acknowledge that not all patients receiving HD are ideally suited for an AVF. Nonetheless, improved referral for AVF placement before dialysis initiation and improved conversion of failing AVGs to AVFs may increase AVF use among patients in whom they are appropriate.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000827/pdfft?md5=cf69ae735b1b975e80cfe9feaf03a257&pid=1-s2.0-S2590059524000827-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141696549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor Estimated Glomerular Filtration Rate With or Without Body Surface Area Indexing and Kidney Transplant Graft Survival","authors":"Syed Ali Husain MD, MPH,&nbsp;Kristen L. King MPH,&nbsp;Sumit Mohan MD","doi":"10.1016/j.xkme.2024.100866","DOIUrl":"10.1016/j.xkme.2024.100866","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000773/pdfft?md5=4261843ea5f9164f9e90bbcc56a7d377&pid=1-s2.0-S2590059524000773-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141709077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Dialysis: Leveraging Big Data and Artificial Intelligence","authors":"Ehsan Nobakht,&nbsp;Wubit Raru,&nbsp;Sherry Dadgar,&nbsp;Osama El Shamy","doi":"10.1016/j.xkme.2024.100868","DOIUrl":"10.1016/j.xkme.2024.100868","url":null,"abstract":"<div><p>The long-term mortality of patients with kidney failure remains unacceptably high. There are a multitude of reasons for the unfavorable status quo of dialysis care, such as the inadequate and suboptimal pattern of uremic toxin removal resulting in a metabolic and hemodynamic “roller coaster” induced by thrice-weekly in-center hemodialysis. Innovation in dialysis delivery systems is needed to build an adaptive and self-improving process to change the status quo of dialysis care with the aim of transforming it from being reactive to being proactive. The introduction of more physiologic and smart dialysis systems using artificial intelligence (AI) incorporating real-time data into the process of dialysis delivery is a realistic target. This would enable machine learning from both individual and collective patient treatment data. This has the potential to shift the paradigm from the practice of population-driven, evidence-based data to precision medicine. In this review, we describe the different components of an AI system, discuss the studied applications of AI in the field of dialysis, and outline parameters that can be used for future smart, adaptive dialysis delivery systems. The desired output is precision dialysis; a self-improving process that has the ability to prognosticate and develop instant and individualized predictive models.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000797/pdfft?md5=034a97d4f20c25dca8e127983018e16f&pid=1-s2.0-S2590059524000797-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141705360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling Nuances in Revascularization: A Call for Focused Exploration in Peritoneal Dialysis Patients","authors":"Özant Helvacı MD","doi":"10.1016/j.xkme.2024.100870","DOIUrl":"10.1016/j.xkme.2024.100870","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000815/pdfft?md5=7b435dbb5b504cdf67cd0022b61b4c5d&pid=1-s2.0-S2590059524000815-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141699686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Hemodiafiltration versus Hemodialysis in End-Stage Kidney Disease: A Systematic Review and Meta-Analysis (Kidney Med. 2024;6(6):100829)","authors":"","doi":"10.1016/j.xkme.2024.100869","DOIUrl":"10.1016/j.xkme.2024.100869","url":null,"abstract":"","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000803/pdfft?md5=246cf093c66b31fa4defcc15ccbdbec0&pid=1-s2.0-S2590059524000803-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}